# Executive function and the other trial

> Cognition at Menopause Consultants — Menopause Consultants compares a cognitive trial in older adults with a separate HIV trial, asking how far the measured executive-function result reaches.

**Cognitive outcomes**

A favourable cognitive result deserves a close look. A separate trial with no significant neurocognitive benefit deserves equal space.

## The older-adult trial

A [20-week controlled trial involving 152 older adults, including 66 with mild cognitive impairment](https://pubmed.ncbi.nlm.nih.gov/22869065/), tested GHRH/tesamorelin. It reported improved executive function, a trend in verbal memory and increased IGF-1. The cognitive effects were comparable in the participants with mild cognitive impairment and the healthy participants.

I welcome the shift from a hormone measurement to a cognitive outcome in this experiment. Executive function was the favourable finding. Verbal memory was reported as a trend, which deserves to remain a trend when the result is described.

The reported population was older adults. A menopause-specific cognitive result would require a more specific study. The executive-function finding can be interesting on its own terms.

![A still life of wooden sorting pieces, a pencil and blank cards on an ochre table](images/cognitive-table.webp)

*An imagined cognitive-testing still life accompanying the [older-adult trial](https://pubmed.ncbi.nlm.nih.gov/22869065/); it does not reproduce the study tasks.*

## A different cognitive result in HIV

A [Phase 2 trial in virally suppressed people with HIV and abdominal obesity](https://pubmed.ncbi.nlm.nih.gov/39813152/) found that tesamorelin reduced waist circumference compared with standard care, while the between-group improvement in neurocognitive function was not statistically significant.

The coexistence of those outcomes is instructive. A physical measurement changed without a significant neurocognitive benefit in that trial. I give the waist result credit for a physical change, with the cognitive question still requiring its own answer.

This was a different population from the older-adult trial. To me, the trials answer different questions and cannot cancel each other out. They leave a more specific question about which cognitive outcomes might change, and in whom.

> The cognitive findings differ across these trials. Their populations and measured outcomes remain part of the account.

## A menopause-specific cognitive question

The [older-adult trial](https://pubmed.ncbi.nlm.nih.gov/22869065/) supports interest in its measured executive-function finding. The [HIV trial](https://pubmed.ncbi.nlm.nih.gov/39813152/) limits a broader claim about reliable neurocognitive improvement. Neither article supplies a trial of menopause-related cognitive symptoms.

A future study specifying the symptom, the participants and the cognitive tasks could give a menopause claim the substance I am looking for. That remains a wish for future work.

A physiological dependency and a clinical outcome require separate explanations. A hormone response, an executive-function result and relief of a particular person's symptoms are distinct questions. I can welcome the executive-function result while leaving the symptom question open.

---

At Menopause Consultants I examine what hormonal responses depend on in published research; this essay site is no consulting business, and its discussion provides no medical advice.